fluocinolone acetonide; neomycin sulfate - Profile

What are the generic sources for fluocinolone acetonide; neomycin sulfate and what is the scope of freedom to operate?

Fluocinolone acetonide; neomycin sulfate is the generic ingredient in one branded drug marketed by Eurofarma and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for fluocinolone acetonide; neomycin sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for fluocinolone acetonide; neomycin sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eurofarma	NEO-SYNALAR	fluocinolone acetonide; neomycin sulfate	CREAM;TOPICAL	060700-001	Approved Prior to Jan 1, 1982		RX	No	Yes

Investment Scenario and Fundamentals Analysis for Fluocinolone Acetonide and Neomycin Sulfate

Last updated: February 5, 2026

Overview

Fluocinolone acetonide and neomycin sulfate are active ingredients used in combination or separately in topical and systemic pharmaceutical products. Their market prospects depend on patent status, therapeutic positioning, regulatory pathways, and commercial landscape.

Product Profiles

• Fluocinolone Acetonide: A corticosteroid with anti-inflammatory activity. Prescribed for conditions like dermatitis, eczema, and inflammatory skin diseases. Available in topical formulations and long-acting implants.

• Neomycin Sulfate: An aminoglycoside antibiotic used in topical preparations to treat bacterial skin infections. Also incorporated into combination products for complex wound management.

Market Dynamics

Parameter	Data Point	Source
Global corticosteroid market size	$13.2 billion (2022), CAGR 4.8% (2022–2027)	MarketsandMarkets [1]
Topical antibiotics market size	Estimated at $2.7 billion (2022)	ResearchAndMarkets [2]
Key approvals and patents	Many patents expired or nearing expiration	FDA/EMA patent databases
Clinical pipeline activity	Moderate; few novel formulations in advanced stages	ClinicalTrials.gov [3]

Regulatory and Patent Considerations

• Many patents for fluocinolone acetonide formulations expired or are nearing expiration, increasing generic competition.
• Neomycin sulfate products face patent expiration, with numerous generics in the market.
• Regulatory pathways favor existing formulations for established drugs; approvals may focus on new indications or delivery mechanisms.

Commercial and R&D Trends

• Shift toward sustained-release implants for fluocinolone acetonide (e.g., eye implants), expanding the therapeutic scope.
• Development of combination topical products for resistant bacterial infections involving neomycin sulfate.
• Increasing interest in biosimilar and generic options, reducing revenue potential for brand-name products.

Investment Implications

• Brand-Name Manufacturers: Risk of revenue decline due to patent expirations; opportunities in formulation enhancements or new indications.
• Generic Manufacturers: High potential, with established manufacturing processes and existing market share.
• Innovators and Biotech Firms: Focus on delivery system innovation, such as long-acting implants for fluocinolone acetonide.
• Regulatory Environment: Regulatory appetite favors existing products for repurposing but may pose barriers for novel combination therapies.

Emerging Opportunities and Risks

• Opportunities:
  • Development of sustained-release drugs.
  • Expansion into new therapeutic areas (e.g., ocular inflammation).
  • Formulation improvements to reduce side effects.
• Risks:
  • Price erosion from generics.
  • Regulatory delays for new formulations.
  • Market saturation for topical antibiotics.

Financial Valuations and Forecasts

• Limited standalone forecasts due to generic competition but potential for growth in specialized formulations.
• Projects focusing on implants or combination drugs could see higher valuation multiples.

Key Takeaways

• The mature status of both APIs limits growth for original brand products.
• Market expansion relies on delivery innovations and new indications.
• Patent landscapes suggest intensifying generic competition.
• Regulation favors incremental advances, not radical innovation.
• Investors should focus on firms with R&D pipelines emphasizing formulation improvements or niche indications.

FAQs

1. What is the main driver for investing in fluocinolone acetonide?
   The development of sustained-release implants and expanding indications in ophthalmology or dermatology.

2. How does patent expiration affect market prospects?
   It opens opportunities for generics, increasing competition and reducing margins for original manufacturers.

3. Are there significant regulatory hurdles?
   Most approvals are straightforward for established formulations, but novel delivery systems may face longer review times.

4. What role do combination products play?
   They can extend patent periods and introduce new therapeutic benefits, creating investment opportunities.

5. How does the market growth outlook look for topical antibiotics like neomycin sulfate?
   Growth is modest and heavily dependent on resistance patterns; market saturation and generics limit upside potential.

Citations

[1] MarketsandMarkets. "Corticosteroids Market." 2022.
[2] ResearchAndMarkets. "Topical Antibiotics Market." 2022.
[3] ClinicalTrials.gov. "Pipeline Data for Fluocinolone and Neomycin-based Products." 2023.